SG10201910522TA - Improved uricase sequences and methods of treatment - Google Patents

Improved uricase sequences and methods of treatment

Info

Publication number
SG10201910522TA
SG10201910522TA SG10201910522TA SG10201910522TA SG10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA
Authority
SG
Singapore
Prior art keywords
treatment
methods
uricase sequences
improved
improved uricase
Prior art date
Application number
SG10201910522TA
Other languages
English (en)
Inventor
Manuel Baca
Andrew C Nyborg
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG10201910522TA publication Critical patent/SG10201910522TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201910522TA 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment SG10201910522TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562162280P 2015-05-15 2015-05-15

Publications (1)

Publication Number Publication Date
SG10201910522TA true SG10201910522TA (en) 2020-01-30

Family

ID=57320301

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201910522TA SG10201910522TA (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment
SG11201708759YA SG11201708759YA (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201708759YA SG11201708759YA (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Country Status (18)

Country Link
US (3) US11098289B2 (enrdf_load_stackoverflow)
EP (1) EP3294322A4 (enrdf_load_stackoverflow)
JP (2) JP2018515101A (enrdf_load_stackoverflow)
KR (1) KR20180002828A (enrdf_load_stackoverflow)
CN (1) CN107614007B (enrdf_load_stackoverflow)
AU (2) AU2016265677B2 (enrdf_load_stackoverflow)
BR (1) BR112017024212A2 (enrdf_load_stackoverflow)
CA (1) CA2984926A1 (enrdf_load_stackoverflow)
CL (1) CL2017002774A1 (enrdf_load_stackoverflow)
CO (1) CO2017012454A2 (enrdf_load_stackoverflow)
HK (1) HK1252542A1 (enrdf_load_stackoverflow)
IL (1) IL255403A0 (enrdf_load_stackoverflow)
MX (1) MX2017014547A (enrdf_load_stackoverflow)
MY (1) MY190411A (enrdf_load_stackoverflow)
RU (1) RU2752497C2 (enrdf_load_stackoverflow)
SG (2) SG10201910522TA (enrdf_load_stackoverflow)
WO (1) WO2016187026A1 (enrdf_load_stackoverflow)
ZA (1) ZA201708507B (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY190411A (en) 2015-05-15 2022-04-21 Medimmune Llc Improved uricase sequences and methods of treatment
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN112410313A (zh) * 2019-08-20 2021-02-26 中国科学院上海药物研究所 一种高热稳定性尿酸酶及其应用
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
WO2021083278A1 (en) * 2019-10-29 2021-05-06 Westlake Therapeutics (Hangzhou) Co. Limited Engineering red blood cells for treating gout and hyperuricemia diseases
WO2022065913A1 (ko) 2020-09-25 2022-03-31 주식회사 프로앱텍 요산산화효소-알부민 접합체, 그 제조방법 및 용도
US20230374471A1 (en) * 2020-10-13 2023-11-23 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
WO2022214086A1 (zh) * 2021-04-09 2022-10-13 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
KR20240049312A (ko) * 2021-07-08 2024-04-16 주식회사 프로앱텍 Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도
KR20240083169A (ko) * 2021-09-23 2024-06-11 주식회사 프로앱텍 Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트
WO2023064732A1 (en) * 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
CN119752761B (zh) * 2025-03-07 2025-06-17 北京化工大学 一种高产heparosan的基因工程菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09154581A (ja) * 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
JP2002524053A (ja) 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
ATE498409T1 (de) * 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
IL141220A0 (en) * 1998-08-06 2002-03-10 Mountain View Pharmaceuticals Conjugates of peg-urate oxidase and use thereof
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
KR101304289B1 (ko) * 2005-04-11 2013-09-12 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
EP2840142B1 (en) * 2007-06-06 2018-12-26 Monsanto Technology LLC Genes and uses for plant enhancement
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement
CZ2011827A3 (cs) 2009-06-25 2012-09-26 Savient Pharmaceuticals, Inc. Zpusoby a sady pro predpovídání rizika reakce na infuzi a ztráty odezvy zpusobené protilátkami, monitorováním kyseliny mocové v séru behem lécby pegylovanou urikázou
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
MY190411A (en) 2015-05-15 2022-04-21 Medimmune Llc Improved uricase sequences and methods of treatment

Also Published As

Publication number Publication date
AU2016265677B2 (en) 2021-12-09
CN107614007A (zh) 2018-01-19
CA2984926A1 (en) 2016-11-24
SG11201708759YA (en) 2017-11-29
HK1252542A1 (zh) 2019-05-31
IL255403A0 (en) 2017-12-31
RU2752497C2 (ru) 2021-07-28
EP3294322A4 (en) 2018-12-12
ZA201708507B (en) 2018-11-28
US20210254024A1 (en) 2021-08-19
MY190411A (en) 2022-04-21
JP2021184733A (ja) 2021-12-09
BR112017024212A2 (pt) 2018-07-17
US20180258406A1 (en) 2018-09-13
AU2022200104A1 (en) 2022-02-03
KR20180002828A (ko) 2018-01-08
AU2016265677A1 (en) 2018-01-04
EP3294322A1 (en) 2018-03-21
CO2017012454A2 (es) 2018-04-30
WO2016187026A1 (en) 2016-11-24
US20190048327A1 (en) 2019-02-14
MX2017014547A (es) 2018-03-15
CL2017002774A1 (es) 2018-04-06
US11098289B2 (en) 2021-08-24
RU2017143580A3 (enrdf_load_stackoverflow) 2019-12-16
JP2018515101A (ja) 2018-06-14
CN107614007B (zh) 2022-03-25
US10883087B2 (en) 2021-01-05
RU2017143580A (ru) 2019-06-17

Similar Documents

Publication Publication Date Title
ZA201708507B (en) Improved uricase sequences and methods of treatment
ZA202006746B (en) Methods of treatment
IL274865A (en) Treatment methods with asparaginase
SI3285777T1 (sl) Glikanski terapevtiki in postopki zdravljenja
ZA201706059B (en) Method of treatment with tradipitant
IL282482A (en) Variants of protoxin-II and methods of use
IL265359A (en) Modified Oligonucleotides and Methods of Use
IL282508A (en) Variants of protoxin-II and methods of use
EP3684342C0 (en) TREATMENT METHOD
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201815588D0 (en) Method of treatment
EP3134108A4 (en) Agents and methods of treatment
ZA201705847B (en) Treatment of pain
GB201706406D0 (en) Method of treatment
IL254825A0 (en) Methods of treatment with Tesalisib
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201621737D0 (en) Compositions and methods of treatment
GB201602802D0 (en) Method of treatment
GB201605127D0 (en) Composition and methods of treatment
GB201417248D0 (en) Compostion and methods of treatment
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment